Nevro (NVRO) Misses Q1 EPS by 78c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Nevro Reports First Quarter 2019 Financial Results
May 9, 2019 4:10 PM EDTREDWOOD CITY, Calif., May 9, 2019 /PRNewswire/ --Â Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the first quarter ended March 31, 2019.
Revenue for the first quarter of 2019 was $82.1 million, a 6% decrease compared to $87.6 million during the prior year period.  U.S. revenue for the first quarter of 2019 was $65.8 million, a 7% decrease compared to $70.6 million in the prior year period.  International revenue was $16.3 million compared to $17.0 million in the prior year period. This... More
